Astrazeneca Plc (AZN:LN)

AstraZeneca Plc (AZN:LN)

Health Care/Pharmaceuticals Price: 8,474.00 GBX Report Date: September 28, 2021 Business Description and Key Statistics

AstraZeneca is a holding company. Through its subsidiaries, Co. is Current YTY % Chg engaged in biopharmaceutical business. Co. focuses on three main therapy areas: oncology - aims to change the practice of medicine Revenue LFY (M) 19,504 5.0 and transform the lives of patients living with cancer; EPS Diluted LFY 1.79 146.9 cardiovascular, renal & metabolism includes treatment of four interrelated conditions - cardiovascular disease, heart failure, Market Value (M) 111,236 metabolic and renal diseases; and respiratory and immunology - aims to transform the treatment of asthma and COPD by Shares Outstanding LFY (000) 1,312,669 eliminating preventable asthma attacks across disease severities Book Value Per Share 8.72 and removing COPD as a cause of death through earlier, biology- led treatment. EBITDA Margin % 28.20 Net Margin % 14.3 Website: www.astrazeneca.com Long-Term Debt / Capital % 54.7 ICB Industry: Health Care Dividends and Yield TTM 2.07 - 2.44% ICB Subsector: Pharmaceuticals Payout Ratio TTM % 90.7 Address: 1 Francis Crick Avenue;Cambridge Biomedical Campus 60-Day Average Volume (000) 3,565 Cambridge 52-Week High & Low 8,845.00 - 6,794.00 GBR Employees: 76,100 Price / 52-Week High & Low 0.96 - 1.25

Price, Moving Averages & Volume

8,947.6 8,947.6 AstraZeneca Plc is currently trading at 8,474.00 which is 0.7% above its 50 day moving 8,665.5 8,665.5 average price of 8,417.36 and 7.7% above its 200 day 8,383.5 8,383.5 moving average price of 7,864.72.

8,101.5 8,101.5 AZN:LN is currently 4.2% below its 52-week high price of 8,845.00 and is 24.7% above 7,819.5 7,819.5 its 52-week low price of 6,794.00. Over the past 52- 7,537.5 7,537.5 weeks, AZN:LN is down 0.4% while on a calendar year-to- date basis it is up 15.7%. 7,255.5 7,255.5 The Relative Strength Index (RSI) indicator for AZN:LN is 6,973.5 6,973.5 currently 50.52. An RSI value of 70 and above is considered 6,691.5 6,691.5 overbought and 30 and below 10/20 11/20 12/20 1/21 2/21 3/21 4/21 5/21 6/21 7/21 8/21 9/21 oversold. Volume (000) 63,269 63,269

47,452 47,452

31,634 31,634

15,817 15,817

Mean (2871.23) 0 0 10/20 11/20 12/20 1/21 2/21 3/21 4/21 5/21 6/21 7/21 8/21 9/21

Price Price (50-Day Simple Moving Average) Price (200-Day Simple Moving Average)

Health Care/Pharmaceuticals Price: 8,474.00 GBX Report Date: September 28, 2021 Price Performance, Technical Indicators & Risk Metrics

Difference Price Performance % Change vs FTSE 350 Technical Indicators 1-Day % -1.09 -0.31 50-Day Average Price 8417.36 1-Week % -2.71 -3.96 Price / 50-Day Average 1.01 4-Week % -0.47 1.61 200-Day Average Price 7864.72 52-Week % -0.41 -21.45 Price / 200-Day Average 1.08 RSI - Relative Strength Index 50.52 Quarter-to-Date % -2.41 -2.89

Year-to-Date % 15.70 6.19 Risk Metrics Last Month % 2.98 1.06 Price Volatility 242.32 Last Quarter % 19.82 15.15 Sharpe Ratio 0.15 Last Calendar Year % -3.72 9.27 Sortino Ratio 0.30

5-Year Price Performance vs. FTSE 350

AstraZeneca Plc Current: 1.69 CAGR: 11.1% Over the past five years, FTSE 350 Index Current: 1.18 CAGR: 3.3% AstraZeneca Plc's stock price is up 69.3% which is 51.7% 1.9 1.9 above the FTSE 350 Index performance of 17.6% over the same period. AstraZeneca 1.8 1.8 Plc's cumulative annualized growth rate (CAGR) over the five year period has been 1.7 AZN:LN 1.7 11.1% while that of the FTSE 350 Index has been 3.3%. 1.6 1.6 Over the past year, AstraZeneca Plc's stock price 1.5 1.5 performance of -0.4% has underperformed that of the 1.4 1.4 FTSE 350 Index by 21.5%. On a year-to-date basis, AstraZeneca Plc's stock price 1.3 1.3 performance of 15.7% has underperformed the FTSE 1.2 1.2 350 Index by 6.2%. ^NMX:LN Over the past week, 1.1 1.1 AstraZeneca Plc's stock price performance of -2.7% has underperformed that of the 1.0 1.0 FTSE 350 Index by 4.0%.

0.9 0.9

0.8 0.8 2017 2018 2019 2020 2021 2022

Health Care/Pharmaceuticals Price: 8,474.00 GBX Report Date: September 28, 2021 Growth and Profitability Metrics

5-Year 10-Year Historical Growth 3-Year 5-Year 10-Year Profitability Current Average Average Revenues % 8.3 4.9 -0.1 Gross Margin % 79.3 80.0 80.1 Revenues Per Share % 7.0 4.1 0.8 EBITDA Margin % 28.2 30.5 30.9 EBITDA % 6.7 5.5 -4.2 Pre-Tax Margin % 16.6 11.7 14.9 EPS Diluted % 11.4 8.3 -4.6 Net Margin % 14.3 11.6 13.2 Free Cash Flow % 37.4 13.8 -3.3 Return on Equity % 25.2 20.1 19.8 Cash from Operations % 25.8 10.3 -3.3 Return on Capital % 12.5 8.8 11.4 Book Value % -0.1 -2.4 -1.9 Return on Assets % 6.2 4.3 6.2

Revenue (M) AstraZeneca Plc's cumulative annualized revenue growth Current: 19503.79 Median: 18464.86 High: 19503.79 Low: 16632.24 CAGR: 1.1% rate over the charted period is 20,078.1 20,078.1 19,503.8 1.1%. This compares to cumulatative annualized 18,698.7 18,881.6 18,464.9 18,881.6 growth of 8.3% over the past 3 years. 17,685.1 17,301.6 17,685.1 16,632.2 16,488.7 16,488.7 2017 2018 2019 2020 2021 AstraZeneca Plc's cumulative EPS Diluted annualized EPS growth rate Current: 1.79 Median: 1.75 High: 2.24 Low: 0.78 CAGR: -5.4% over the charted period is 2.53 2.53 -5.4%. This compares to 2.24 cumulatative annualized 1.92 1.75 1.79 1.92 growth of 11.4% over the past 3 years. 1.33 1.32 1.32 0.78 0.71 0.71 2016 2017 2018 2019 2020 2021

Net Profit Margin % AstraZeneca Plc's net profit margin of 14.3% is 2.7% Current: 14.30 Median: 11.27 High: 17.89 Low: 5.52 CAGR: 7.4% above the period's mean net 18.5 18.5 margin of 11.6%. During the charted period, the observed 14.0 14.0 net profit margin high and low Mean (11.55) were 17.9% and 5.5% 9.4 9.4 respectively.

4.9 4.9 2016 2017 2018 2019 2020 2021 AstraZeneca Plc's return on Return on Equity % equity of 25.2% is 5.1% above Current: 25.20 Median: 20.00 High: 28.50 Low: 10.70 CAGR: 10.5% the period's mean return on 29.4 29.4 equity of 20.1%. During the charted period, the observed 22.9 22.9 ROE high and low were 28.5% Mean (20.07) and 10.7% respectively. 16.3 16.3

9.8 9.8 2016 2017 2018 2019 2020 2021

Health Care/Pharmaceuticals Price: 8,474.00 GBX Report Date: September 28, 2021 Valuation Metrics

5-Year 10-Year 5-Year 10-Year Current Median Median Current Median Median

Price / EPS TTM 37.1 38.1 35.8 Earnings Yield % 2.67 2.62 2.80

Price / Sales 5.3 4.6 3.5 Free Cash Flow Yield % 3.80 2.17 3.80

Price / Operating Cash Flow 20.8 17.6 15.3 Dividend Yield % 2.44 3.37 4.08

Price / Book Value 9.7 8.2 5.2 Enterprise Value / EBITDA 20.3 17.4 14.8

Price / EPS TTM AstraZeneca Plc is trading at 37.11 times its EPS generated Current: 37.11 Median: 38.05 High: 97.72 Low: 18.08 CAGR: -2.6% during the latest fiscal year. 101.7 101.7 This multiple is below the historically observed median 72.5 72.5 of 38.05, while high and low observations have been 97.72 and 18.08. 43.3 Median (38.05) 43.3

14.1 14.1 2016 2017 2018 2019 2020 2021 Price / Sales AstraZeneca Plc is trading at a Price to Sales ratio of 5.31 Current: 5.31 Median: 4.56 High: 5.91 Low: 2.99 CAGR: 6.9% based on sales generated 6.06 6.06 during the latest fiscal year. This ratio is above the 4.99 4.99 historically observed median Median (4.56) ratio of 4.56, while high and low observations have been 3.91 3.91 5.91 and 2.99.

2.84 2.84 2016 2017 2018 2019 2020 2021 AstraZeneca Plc is trading at a Price / Book Value Price to Book ratio of 9.72 Current: 9.72 Median: 8.18 High: 13.53 Low: 4.44 CAGR: 9.1% based on book value at the 14.0 14.0 latest fiscal year end. This ratio is above the historically observed median of 8.18, 10.7 10.7 while high and low Median (8.18) observations have been 13.53 7.3 7.3 and 4.44.

4.0 4.0 2016 2017 2018 2019 2020 2021 AstraZeneca Plc has a Free Free Cash Flow Yield % Cash Flow Yield of 3.80% Current: 3.80 Median: 2.17 High: 4.49 Low: 0.19 CAGR: 9.6% based on free cash flow 4.7 4.7 generated during the latest fiscal year. This value is above the historically observed 3.1 3.1 median yield of 2.17%, while Median (2.17) high and low observations 1.6 1.6 have been 4.49 and 0.19.

0.0 0.0 2016 2017 2018 2019 2020 2021

Health Care/Pharmaceuticals Price: 8,474.00 GBX Report Date: September 28, 2021 Dividends Data

Dividends Per Share TTM 2.07 Payout Ratio TTM % 90.65% Dividend Yield TTM % 2.44%

Rate Ex Date Record Date Payment Date Currency Note 0.000 12-08-2021 13-08-2021 13-09-2021 1ST INTERIM GROSS 1.374 25-02-2021 26-02-2021 29-03-2021 GBP 2ND INTERIM GROSS 0.696 13-08-2020 14-08-2020 14-09-2020 GBP 1ST INTERIM GROSS 1.464 27-02-2020 28-02-2020 30-03-2020 GBP 2ND INTERIM GROSS 0.719 08-08-2019 09-08-2019 09-09-2019 GBP INTERIM GROSS 1.468 28-02-2019 01-03-2019 27-03-2019 GBP 2ND INTERIM GROSS 0.684 09-08-2018 10-08-2018 10-09-2018 GBP 1ST INTERIM GROSS 1.336 15-02-2018 16-02-2018 19-03-2018 GBP 2ND INTERIM GROSS 0.689 10-08-2017 11-08-2017 11-09-2017 GBP 1ST INTERIM GROSS 1.502 16-02-2017 17-02-2017 20-03-2017 GBP 2ND INTERIM GROSS 0.687 11-08-2016 12-08-2016 12-09-2016 GBP 1ST INTERIM GROSS 1.310 18-02-2016 19-02-2016 21-03-2016 GBP 2ND INTERIM NET

Dividend Growth and Yield

Dividends Per Share TTM AstraZeneca Plc's trailing 12- month dividend per share is Current: 2.07 Median: 2.16 High: 2.19 Low: 2.00 CAGR: 0.7% 2.07 and its dividend has 2.20 2.20 grown at a cumulative annualized rate of 0.7% over 2.16 2.16 the charted period. This compares to dividend growth 2.13 2.13 of -5.20% over the past year and cumulative annualized growth of 0.70% over the past 2.09 2.09 3 years.

2.06 2.06

2.03 2.03

1.99 1.99 2016 2017 2018 2019 2020 2021

Dividend Yield TTM % AstraZeneca Plc's current dividend yield is 2.44% based Current: 2.44 Median: 3.37 High: 4.99 Low: 2.34 CAGR: -8.3% on trailing 12 month 5.12 5.12 dividends. The current yield is below the historically observed 4.64 4.64 median of 3.37% and, over the charted time period, the 4.15 4.15 observed high yield has been 4.99% and the observed low yield has been 2.34%. 3.67 3.67

3.18 3.18

2.69 2.69

2.21 2.21 2016 2017 2018 2019 2020 2021

Health Care/Pharmaceuticals Price: 8,474.00 GBX Report Date: September 28, 2021 ICB Subsector Peer Comparisons

Price Change Year to Date % Price Change Last Calendar Year % -20.5 9.4 39.2 69.1 99.0 -56.1 5.5 67.0 128.6 190.2

Indivior PLC 93.6 Indivior PLC 179.0 Novo-Nordisk AS 43.3 Recipharm AB 45.8 Dechra Pharmaceuticals Plc 37.0 Vectura Group Plc 34.4 Vectura Group Plc 32.1 Peer Group Average 30.2 Peer Group Average 24.4 Hikma Pharmaceuticals Plc 26.5 Alliance Pharma PLC 17.4 HUTCHMED (China) Ltd 21.1 HUTCHMED (China) Ltd 17.0 Recordati-Industria Chimica e… 20.6 AstraZeneca Plc 15.7 Dechra Pharmaceuticals Plc 19.0 Recordati-Industria Chimica e… 8.0 Novo-Nordisk AS 10.0 Recipharm AB 6.1 Alliance Pharma PLC 4.2 GlaxoSmithKline Plc 3.1 AstraZeneca Plc -3.7 Hikma Pharmaceuticals Plc -5.2 GlaxoSmithKline Plc -24.6 -20.5 9.4 39.2 69.1 99.0 -56.1 5.5 67.0 128.6 190.2

Price / EPS TTM Price / Book Value 0.0 26.1 52.1 78.2 104.3 0.0 5.9 11.8 17.6 23.5

Dechra Pharmaceuticals Plc 99.9 Novo-Nordisk AS 22.5 Vectura Group Plc 99.9 HUTCHMED (China) Ltd 11.0 HUTCHMED (China) Ltd 99.9 AstraZeneca Plc 9.7 Peer Group Average 46.6 Indivior PLC 9.7 Recipharm AB 46.1 Dechra Pharmaceuticals Plc 8.0 AstraZeneca Plc 37.1 Recordati-Industria Chimica e… 7.9 Novo-Nordisk AS 33.5 Peer Group Average 7.7 Recordati-Industria Chimica e… 29.2 GlaxoSmithKline Plc 4.8 Alliance Pharma PLC 21.8 Hikma Pharmaceuticals Plc 3.5 Hikma Pharmaceuticals Plc 18.0 Recipharm AB 2.8 Indivior PLC 15.5 Vectura Group Plc 2.4 GlaxoSmithKline Plc 12.1 Alliance Pharma PLC 2.0 0.0 26.1 52.1 78.2 104.3 0.0 5.9 11.8 17.6 23.5

EPS 5-Year Growth Rate % Revenue 5-Year Growth Rate % -55.2 -20.1 15.0 50.2 85.3 -9.9 2.4 14.8 27.2 39.5

HUTCHMED (China) Ltd 78.9 Vectura Group Plc 37.3 Recordati-Industria Chimica e… 11.8 Alliance Pharma PLC 25.5 Hikma Pharmaceuticals Plc 9.4 Recipharm AB 23.8 Alliance Pharma PLC 8.4 Dechra Pharmaceuticals Plc 20.4 Dechra Pharmaceuticals Plc 8.3 Peer Group Average 13.1 AstraZeneca Plc 8.3 Hikma Pharmaceuticals Plc 12.0 Peer Group Average 6.6 GlaxoSmithKline Plc 7.5 Novo-Nordisk AS 6.5 HUTCHMED (China) Ltd 6.8 Recipharm AB 4.1 Recordati-Industria Chimica e… 6.7 GlaxoSmithKline Plc -8.0 AstraZeneca Plc 4.9 Indivior PLC -17.6 Novo-Nordisk AS 2.9 Vectura Group Plc -37.2 Indivior PLC -3.6 -55.2 -20.1 15.0 50.2 85.3 -9.9 2.4 14.8 27.2 39.5

Health Care/Pharmaceuticals Price: 8,474.00 GBX Report Date: September 28, 2021 Abbreviations: CAGR - Cumulative annual growth rate. EBIT - Earnings before interest and taxes. EBITDA - Earnings before interest, taxes, depreciation & amortization. LFY - Last fiscal year M - Million LON - London Stock Exchange

Definitions: Market Value - Weekly Price times latest Shares Outstanding times any applicable ADR factor. Revenue - Sum of the last four quarters of Revenues. Revenue Per Share - Sum of the last four quarters of Total Revenue divided by Weighted Average Shares Outstanding. Operating EPS LFY - EPS excluding non-recurring, non-operating items, fiscal year aligned TTM value. 60-Day Average Volume (000) - The average of the last 60 daily volume values in thousands of shares. Price 52-Week High - The high closing price from the last 52 weeks of daily closing prices. Price 52-Week Low - The low closing price from the last 52 weeks of daily closing prices. Price / 52-Week High - Latest price divided by the high price from the past 52 weeks of daily closing prices. Price / 52-Week Low - Latest price divided by the low price from the past 52 weeks of daily closing prices. 50-Day Average Price - Mean of last 50 daily closing prices. 200-Day Average Price - Mean of last 200 daily closing prices. Price / 50-Day Average Price - Latest closing price divided by mean of last 50 daily closing prices, as a percentage. Price / 200-Day Average Price - Latest closing price divided by mean of last 200 daily closing prices, as a percentage. Relative Strength Index - Relative Strength Index or RSI measures the magnitude of gains over a given time period against the magnitude of losses over that period. The equation is RSI = 100 - 100 / (1 + RS) where RS = (total gains / n) / (total losses / n) and n = number of RSI periods. In this item, 14 days is used and one year of daily prices are considered. A value of 30 or below may imply oversold and 70 or above may imply overbought. Price Volatility - The standard deviation of the last 20 days of daily closing prices. Sharpe Ratio - The 5 year average of the excess monthly return over the risk - free rate(1 - month T - bill) over the 5 year standard deviation of the same series. Sortino Ratio - The same calculation as the Sharpe Ratio but with positive excess returns set to zero for the standard deviation denominator, so only negative volatility weighs in. Dividends Per Share TTM - Sum of the last four quarters of Dividends Per Share. Payout Ratio - Dividends Per Share TTM divided by Operating EPS TTM. Dividend Yield TTM % - Sum of the last four quarter of Dividends Per Share divided by Weekly Price. EBITDA - Sum of the last four quarters of EBITDA (Operating Income + Depreciation & Amortization). Free Cash Flow - Sum of the last four quarters Net Cash from Operations minus Capital Expenditures (Purchase of Property, Plant & Equipment), from the Cash Flow Statement. Book Value Per Share - Total Common Equity last quarter divided by Shares Outstanding last quarter. Gross Margin % - Sum of the last four quarters Gross Profit divided by the sum of the last four quarters Revenues. EBITDA Margin % - Sum of the last four quarters EBITDA divided by the sum of the last four quarters Revenues. Pre-Tax Margin % - Sum of the last four quarters of Earnings Before Taxes divided by sum of the last four quarters Revenues. Net Profit Margin % - Sum of the last four quarters of Operating EPS divided by sum of the last four quarters Revenues Per Share. Return on Equity % - Sum of the last four quarters of Operating EPS divided by the average of the last four quarters Book Value. Return on Capital % - Sum of the last four quarters of Operating EPS divided by the average of the last four quarters Total Capital Per Share. Return on Assets % - Sum of the last four quarters of Operating EPS divided by the average of the last four quarters Total Assets Per Share. Price / EPS TTM - Weekly Price divided by the sum of the last four quarters of Operating EPS (capped at 99.9). Price / Sales - Weekly Price divided by Revenues Per Share TTM. Price / Book Value - Weekly Price divided by Book Value Per Share last quarter. Book Value Per Share is Total Common Equity last quarter divided by Shares Outstanding last quarter (capped at 49.9). Free Cash Flow Yield % - Free Cash Flow Per Share TTM divided by Weekly Price. Enterprise Value - Market Value plus Total Debt last year plus Preferred Equity last year minus Cash & Cash Equivalents last year. Enterprise Value / Sales - Enterprise Value divided by the sum of the last four quarters of Revenue. Enterprise Value / EBITDA - Enterprise Value divided by EBITDA TTM. Enterprise Value / EBIT - Enterprise Value divided by trailing four quarters of Operating Income. Enterprise Value / Free Cash Flow- Enterprise Value divided by the sum of the last four quarters of Free Cash Flow. Russell 1000 Index - The largest 1,000 stocks by market cap, the index comprehensively covers the US large cap universe. EPS 5-Year Growth Rate % is capped at 999.9%. Revenue 5-Year Growth Rate % is capped at 999.9%.

Health Care/Pharmaceuticals Price: 8,474.00 GBX Report Date: September 28, 2021

Disclaimer:

© 2021 London Stock Exchange Group plc and its applicable group undertakings (the “LSE Group”). The LSE Group includes (1) FTSE International Limited (“FTSE”), (2) Frank Russell Company (“Russell”), (3) FTSE Global Debt Capital Markets Inc. and FTSE Global Debt Capital Markets Limited (together, “FTSE Canada”), (4) MTSNext Limited (“MTSNext”), (5) Mergent, Inc. (“Mergent”), (6) FTSE Fixed Income LLC (“FTSE FI”) and (7) The Yield Book Inc (“YB”). All rights reserved.

FTSE Russell® is a trading name of FTSE, Russell, FTSE Canada, MTSNext, Mergent, FTSE FI, YB. “FTSE®”, “Russell®”, “FTSE Russell®”, “MTS®”, “FTSE4Good®”, “ICB®”, “Mergent®”, “The Yield Book®” and all other trademarks and service marks used herein (whether registered or unregistered) are trademarks and/or service marks owned or licensed by the applicable member of the LSE Group or their respective licensors and are owned, or used under licence, by FTSE, Russell, MTSNext, FTSE Canada, Mergent, FTSE FI, YB. FTSE International Limited is authorised and regulated by the Financial Conduct Authority as a benchmark administrator.

All information is provided for information purposes only. All information and data contained in this publication is obtained by the LSE Group, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error as well as other factors, however, such information and data is provided "as is" without warranty of any kind. No member of the LSE Group nor their respective directors, officers, employees, partners or licensors make any claim, prediction, warranty or representation whatsoever, expressly or impliedly, either as to the accuracy, timeliness, completeness, merchantability of any information or of results to be obtained from the use of FTSE Russell indexes or data or the fitness or suitability of the FTSE Russell indexes or data for any particular purpose to which they might be put. Any representation of historical data accessible through FTSE Russell indexes or data is provided for information purposes only and is not a reliable indicator of future performance.

No responsibility or liability can be accepted by any member of the LSE Group nor their respective directors, officers, employees, partners or licensors for (a) any loss or damage in whole or in part caused by, resulting from, or relating to any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analysing, editing, transcribing, transmitting, communicating or delivering any such information or data or from use of this document or links to this document or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if any member of the LSE Group is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, such information.

No member of the LSE Group nor their respective directors, officers, employees, partners or licensors provide investment advice and nothing contained in this document or accessible through FTSE Russell indexes or data, including statistical data and industry reports, should be taken as constituting financial or investment advice or a financial promotion.

No part of this information may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the applicable member of the LSE Group. Use and distribution of the LSE Group data requires a licence from FTSE, Russell, FTSE Canada, MTSNext, Mergent, FTSE FI, YB, and/or their respective licensors.